Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET)
imaging and how well it works to detect CD46 positive cancer cells in patients with multiple
myeloma. [89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A
radiopharmaceutical tracer uses a small amount of radioactive material that is injected into
a vein to help image different areas of the body. [89Zr]DFO-YS5 targets a specialized protein
called CD46, which is in certain multiple myeloma cancer cells, and [89Zr]DFO-YS5 PET scans
may improve detection of multiple myeloma.